Drugs / 61Cu-NODAGA-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06736054 | Oct 2024 → Mar 2025 overdue | prostate adenocarcinoma | Hoag Memorial Hospital Presbyterian | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 61Cu-NODAGA-PSMA | “imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV)” NCT06736054 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT06736054 ↗ |